story of the week
Subcutaneous Rituximab as First-Line Treatment for Low–Tumor Burden Follicular Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
J. Clin. Oncol 2023 Apr 18;[EPub Ahead of Print], G Cartron, E Bachy, H Tilly, N Daguindau, GM Pica, F Bijou, C Mounier, A Clavert, GL Damaj, B Slama, O Casasnovas, R Houot, K Bouabdallah, D Sibon, O Fitoussi, N Morineau, C Herbaux, T Gastinne, LM Fornecker, C Haioun, V Launay, C Araujo, O Benbrahim, L Sanhes, R Gressin, H Gonzalez, F Morschhauser, D Ternant, L Xerri, K Tarte, D PrangerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.